Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Increases By 38.4%

Posted by Latisha Jones on Oct 15th, 2024

Entera Bio Ltd. (NASDAQ:ENTX – Get Free Report) saw a significant growth in short interest in September. As of September 30th, there was short interest totalling 47,200 shares, a growth of 38.4% from the September 15th total of 34,100 shares. Based on an average daily trading volume, of 41,000 shares, the short-interest ratio is presently 1.2 days.

Institutional Investors Weigh In On Entera Bio

An institutional investor recently bought a new position in Entera Bio stock. Virtu Financial LLC acquired a new stake in Entera Bio Ltd. (NASDAQ:ENTX – Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 22,040 shares of the company’s stock, valued at approximately $37,000. 14.11% of the stock is owned by institutional investors.

Entera Bio Stock Down 3.8 %

Shares of Entera Bio stock opened at $1.79 on Tuesday. Entera Bio has a 52-week low of $0.52 and a 52-week high of $3.35. The firm’s 50 day moving average price is $1.80 and its 200-day moving average price is $1.97. The company has a market cap of $64.06 million, a P/E ratio of -6.39 and a beta of 1.57.

Entera Bio (NASDAQ:ENTX – Get Free Report) last issued its quarterly earnings results on Friday, August 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.06). The business had revenue of $0.06 million for the quarter. As a group, equities research analysts forecast that Entera Bio will post -0.23 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Entera Bio in a research note on Monday, October 7th.

Get Our Latest Report on ENTX

About Entera Bio

(Get Free Report)

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.